UAB Researchers Suggest a Potential New Therapeutic Strategy for HER2+ Breast Cancer

UAB Researchers Suggest a Potential New Therapeutic Strategy for HER2+ Breast Cancer
Researchers at the University of Alabama at Birmingham (UAB) recently revealed a potential new therapy for a subtype of breast cancer, the HER2+ (human epidermal growth factor receptor 2). The study was recently published in the journal Breast Cancer Research and Treatment and is entitled “PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers.” It is estimated that, apart from skin cancer, breast cancer is the most commonly diagnosed cancer among American women, affecting more than 230,000 individuals every year. The death rate in women associated with breast cancer is higher than any other cancer, except for lung cancer. 1 in every 8 American women is predicted to develop invasive breast cancer over the course of her lifetime. There are five different subtypes of breast cancer: HER2-enriched (or HER2+), triple negative (or basal), luminal A, luminal B and unclassified. Each of these subtypes is characterized by a distinct disease, biology, treatment response and progression. A deeper understanding of these differences will allow a more effective and personalized treatment. Previous studies have shown that triple negative breast cancers express high levels of the DNA repair enzyme PARP1 [poly (ADP-ribose) polymerase 1] and that they are sensitive to PARP inhibitors. UAB researchers have reported in 2012 that HER2+ breast cancer cells are also sensitive to PARP inhibitors by interfering with NF-kappaB (nuclear factor kappa-light-chain-e
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.